[Effect of the cytostatic action preparation prospidine on urinary excretion of 17-hydroxycorticosteroids and 17-ketosteroids in reticulodermia].
D000433:1-Propanol / Q000627:therapeutic use; D015065:17-Hydroxycorticosteroids / Q000652:urine*; D015068:17-Ketosteroids / Q000652:urine*; D000328:Adult; D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008206:Lymphatic Diseases / Q000188:drug therapy* / Q000652:urine; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010912:Pituitary-Adrenal Function Tests; D012737:Sex Factors; D013141:Spiro Compounds / Q000627:therapeutic use*
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D000970:Antineoplastic Agents; D010879:Piperazines; D013141:Spiro Compounds; D000433:1-Propanol
Vliianie preparata tsistostaticheckogo deĭstviia prospidina na ékskretsiia 17-oksikortikosteroidov i 17-ketosteroidov s mochoĭ u bol'nykh retikulodermiiami.